

The anti-aggregation activity of new 11-amino acid of erythropoietin derivate containing tripeptide motifs

Actividad antiagregante de nuevos derivados de 11 aminoácidos de la eritropoyetina, que contienen motivos de tripéptidos

Ivan V. Golubev; Vladimir V. Gureev; Liliya V. Korokina; Oleg S. Gudyrev; Tatiana G. Pokrovskaya; Olga N. Pokopeiko; Vladimir M. Pokrovskii; Elena B. Artyushkova; Mikhail V. Korokin

¹Belgorod State University, 85, Pobedy St., Belgorod, 308015, Russia

²Kursk State Medical University, 3, K, Marks St., Kursk, 305003, Russia

*Corresponding author: Mikhail V. Korokin, Kursk State Medical University, 3, K, Marks St., Kursk, 305003, Russia; Email: korokin@bsu.edu.ru

Received/Recibido: 06/28/2020 Accepted/Aceptado: 07/15/2020 Published/Publicado: 09/07/2020 DOI: 10.5281/zenodo.4264989

Abstract

Objective. To study the platelet antiaggregant activity of new 11-amino acid derivatives of erythropoietin, containing tripeptide motifs.

Materials and methods. The platelet aggregation degree was determined using the platelet-rich plasma of male Wistar rats. Formation of platelet aggregates results in an increase in light transmission through the sample; the kinetics of the responses and maximal aggregation provide a quantitative assessment of platelet aggregation. The degree of platelet aggregation is estimated by the magnitude of the amplitude of aggregatograms, and the time of onset of light transmission level as well the time of onset of 85% of light transmission.

Results. When blood was incubated with the studied peptides P- α B1, P- α B3, and P- α B4, a pronounced antiplatelet effect was observed. This is evidenced by a decrease in the maximum light transmittance of the plasma to $28.4 \pm 1.00\%$, $29.7 \pm 1.13\%$ and $30.1 \pm 0.97\%$, respectively, and a delay in its onset to 134.4 ± 2.90 , 135.8 ± 3.72 and 132.0 ± 3.59 seconds, respectively. In this case, a shift in the plasma light transmission curve to the right was observed which characterizes the platelet aggregation process.

Conclusion. The addition of P- α B1, P- α B3, and P- α B4 produces antiplatelet activity, which is reflected by the shifting to the right of the platelet aggregation curve. The data obtained indicate a prolongation of platelet aggregation time and a decrease in its degree.

Keywords: erythropoietin, α -helix B, thrombocytes, aggregation, 11-amino acid peptide.

Resumen

Objetivo. Estudiar la actividad antiagregante plaquetario de los nuevos derivados de 11 aminoácidos de la eritropoyetina, que contienen motivos de tripéptidos.

Materiales y métodos. El grado de agregación plaquetaria se determinó usando el plasma rico en plaquetas de ratas Wistar macho. La formación de agregados de plaquetas resulta en un aumento en la transmisión de luz a través de la muestra. La cinética de las respuestas y la agregación máxima proporcionan una evaluación cuantitativa de la agregación plaquetaria. El grado de agregación plaquetaria se estima por la magnitud de la amplitud de los agregados y el tiempo de inicio del nivel de transmisión de luz, así como el tiempo de inicio del 85% de la luz. Transmisión.

Resultados. Cuando se incubó sangre con los péptidos estudiados P- α B1, P- α B3 y P- α B4, se observó un efecto antiplaquetario pronunciado. Esto se evidencia por una disminución en la transmitancia máxima de luz del plasma a $28,4 \pm 1,00\%$, $29,7 \pm 1,13\%$ y $30,1 \pm 0,97\%$, respectivamente, y un retraso en su inicio a $134,4 \pm 2,90$ s, $135,8 \pm 3,72$ s y $132,0 \pm 3,59$ segundos, respectivamente. En este caso, se observó que la curva de transmisión de luz plasmática se desplazó a la derecha, lo que caracteriza el proceso de agregación plaquetaria.

Conclusión. La adición de P- α B1, P- α B3 y P- α B4 produce actividad antiplaquetaria, que se refleja al desplazarse a la derecha de la curva de agregación plaquetaria. Los datos obtenidos indican una prolongación del tiempo de agregación plaquetaria y una disminución en su grado.

Palabras clave: eritropoyetina, α -hélice B, trombocitos, agregación, péptido de 11 aminoácidos.

Introduction

The high contribution of cardiovascular pathology to the general structure of the causes of mortality and disability in the population of developed countries necessitates their in-depth study and improvement of correction methods. Moreover, as the main task of research in this area, one can designate a precise search for ways to prevent and treat the atherosclerotic process, as the main cause of cardiovascular mortality.

Atherosclerosis is a chronic arterial disease and a major cause of vascular death. Fatty streaks in arterial walls gradually develop into atheroma and characteristic plaques. The acute rupture of these atheromatous plaques causes local thrombosis, leading to partial or total occlusion of the affected artery. The clinical consequences of these plaques depend on their site and the degree and speed of vessel occlusion. The most significant from the epidemiological point of view is the defeat of the coronary and cerebral vessels, leading to such nosologies as coronary heart disease (CHD) and ischemic stroke¹.

Activation of pro-inflammatory cascades in macrophages and endothelium is an important link in atherogenesis. Accumulation of excess lipids within the artery due to the presence of increased circulating LDL promotes endothelial dysfunction and activation, which results in increased production of pro-inflammatory cytokines and reactive oxygen species, overexpression of adhesion molecules, chemokines, CRP, and decreased NO bioavailability. These processes contribute to the recruitment and infiltration of monocytes, which differentiate into macrophages and following the uptake of modified-LDL via scavenger receptors, become foam cells, which are essential steps in atherogenesis²⁻⁷. Oxidative stress, modified lipoproteins, and other factors (bioactive lipids, molecular patterns associated with damage, cytokines) stimulate inflammation through their receptors^{2,3,8}.

Based on the available information on the pathogenesis of atherosclerosis, one of the approaches for influencing atherogenesis is the use of drugs with cytoprotective and mitochondrial-oriented activity. Recent preclinical *in vitro* and *in vivo* studies demonstrated that an endogenous erythropoiesis stimulator with a mass of 34 kDa erythropoietin (EPO) has a high cytoprotective activity, which is mainly associated with effects on the mitochondrial unit and has been confirmed in experimental models of ischemic and traumatic lesions, including endothelium, myocardium, and brain^{9-11,18}. Our previous studies have shown that recombinant erythropoietin and carbamylated darbepoetin have tissue-protective, endothelial, and cardioprotective effects in various experimental models¹²⁻¹⁴.

It has been reported that EPO can bind the tissue-protective receptor (TPR, namely EPOR/CD131 heterodimer) and plays an important role in tissue protection and immune regulation. It was suggested that the α -helix B of EPO, which is exposed to aqueous medium away from the binding sites of EPO and (EPOR)₂, is critical for the recognition of TPR, and it was confirmed that the α -helix B peptide had similar tissue-protective

effects for EPO and CEPO. Based on these observations, an eleven-amino acid linear peptide mimicking the three-dimensional structure of the external aqueous face of the α -helix B peptide was developed and named helix B surface peptide. In the present study, we assessed *in vitro* the antiaggregant activity of new 11-amino acid derivatives of erythropoietin, P- α B1, P- α B3, and P- α B4, containing tripeptide motifs.

Material and Methods

The experimental study was conducted at the Research Institute of Pharmacology of Living Systems of Belgorod State National Research University. The study was performed in compliance with the requirements of General Requirements for the Competence of Testing and Calibration Laboratories 17025-2009, GOST R ISO 5725-2002 and the Rules of Laboratory Practice, approved by Order of the Ministry of Healthcare and Social Development of the Russian Federation dated August 23rd, 2010 № 708n.

The platelet aggregation degree was determined using the platelet-rich plasma of male Wistar rats. Blood was taken from the abdominal aorta into a test tube with a 3.8% sodium citrate solution in a 9:1 ratio, followed by the addition of the test polypeptides at a final concentration of 30 μ g/ml.

The amino acid sequences of the studied peptides are presented in Table 1.

Table 1. Amino acid sequences and laboratory ciphers of innovative peptides studied in this study.

Lab Code	Amino Acid Sequence
P- α B	QEQLERALNSS
P- α B1	RGDQEQLERALNSS
P- α B2	UEQLERALNSSRGD
P- α B3	KGDQEQLERALNSS
P- α B4	UEQLERALNSSKGD
P- α B5	PGPQEQLERALNSS
P- α B6	UEQLERALNSSPGP

The compounds were incubated for 30 minutes. Then it was centrifuged at 1000 rpm for 10 minutes. After that, 270 μ l of platelet-rich plasma was added to a 0.3 ml aggregometer cuvette. Then, 30 μ l of adenosine-5-diphosphoric acid disodium salt (ADP) was added at a final concentration of 5 μ M. The antiplatelet activity was determined by the G. Born method on a two-channel laser platelet aggregation analyzer ALAT-2 Biola. Reagents manufactured by RENAM. The analysis was carried out no later than 2 hours after the extraction of the blood. Graphically registering platelet aggregation for 5 minutes obtained curves reflecting a decrease in the optical density of the plasma. The degree of platelet aggregation was evaluated by the magnitude of the maximum amplitude of the aggregatogram and the time of onset of maximum light transmission and the time of onset of the level of 85% of the maximum light transmission.

Statistical processing was performed using the software environment of calculations R. The nature of the distribution of characters in the statistical sample was determined

using the Shapiro-Wilk test and the Spiegelhalter criterion, the equality of variances was assessed using the Levene criterion. Depending on the type of distribution of attributes and the equality of variances, the significance of the results was evaluated using parametric (ANOVA) or non-parametric (Kruskal-Wallis test) one-way analysis of variance and unpaired Student t-test was used as a post-hoc analysis to identify differences in intergroup comparisons or the Mann-Whitney test, respectively, adjusted by Benjamini-Hochberg for multiple hypothesis testing. The results were considered significant for $p \leq 0.05$.

Results and Discussion


When using ADP as an inducer, light transmission in the group of intact animals occurs at 120.1 ± 4.03 s and is 37.2 ± 1.55 %. P- α B induced statistically significant increase in platelet aggregation, since after adding ADP the maximum level of light transmission increased to 46.4 ± 2.40 %, and on average it reached 104.3 ± 4.46 s. Therefore, the basic peptide with the protein sequence QEQLERALNSS has pronounced pro-coagulant properties (Fig. 1, Table 2).

When incubating blood with the studied derivatives having tripeptide motifs under the codes P- α B1, P- α B3, and P- α B4, a pronounced antiplatelet effect was observed. This indicates a decrease in plasma light transmittance to 28.4 ± 1.00 %, 29.7 ± 1.13 %, and 30.1 ± 0.97 %, respectively, and an increase in the onset time leads to platelet aggregation to 134.4 ± 2 , 90 s, 135.8 ± 3.72 s and 132.0 ± 3.59 s, respectively (Fig. 1). At the same time, a natural shift in the light transmission curve of the plasma is observed, which indicates a platelet aggregation process that is eligible for a group of intact animals.

P- α B2 did not affect the aggregation ability of platelets in the conducted experiment (Table 2 and Figure 1).

Incubation of blood with P- α B5 and P- α B6 led to an increase in the aggregation ability of platelets to the level of comparative analysis. At the same time, a natural shift to the left in the light transmission curve of the plasma is observed, which indicates a platelet aggregation process, depending on the group of intact animals.

Figure 1. The effect of innovative peptides that mimic the spatial structure of the erythropoietin α -helix B on platelet aggregation ability. Not flooded marker at $p < 0.05$ compared with intact animals.



A logical trend is observed when analyzing the onset time of 85% of the maximum level of light transmission. In the samples: P- α B1, P- α B3, and P- α B4, the time of its onset are longer with respect to the group of intact animals, and this circumstance also contributes to a shift of the platelet aggregation ability curve to the right (Table 2).

Table 2. The effect of innovative peptides that mimic the α -helix of erythropoietin B on the aggregation ability of platelets.

Group	Onset time		
	85 % of the maximum, seconds	Maximum aggregation, seconds	Maximum transmittance, %
Intact	90.1 ± 3.01	120.1 ± 4.03	37.2 ± 1.55
P- α B	74.0 ± 3.83*	104.3 ± 4.36*	46.4 ± 2.40*
P- α B1	101.4 ± 1.85*	134.4 ± 2.90*	28.4 ± 1.00*
P- α B2	90.8 ± 2.56	119.8 ± 119.8	36.7 ± 1.32
P- α B3	104.1 ± 2.88*	135.8 ± 3.72*	29.7 ± 1.13*
P- α B4	99.5 ± 2.84*	132.0 ± 3.59*	30.1 ± 0.97*
P- α B5	80.8 ± 2.94*	107.8 ± 3.87*	45.4 ± 2.04*
P- α B6	79.0 ± 3.34*	105.6 ± 4.17*	45.0 ± 1.64*

* $p < 0.05$ compared with intact animals.

In our previous study we found that the basic 11-amino acid peptide P- α B (QEQLERALNSS), which mimics the structure of erythropoietin α -helix B has a pronounced endothelial-protective and potentially atheroprotective effect due to its ability to prevent the death of endothelial cells, however, it shows pro-thrombotic activity in rats¹⁵, suggesting the requirement for necessitates further modifications of this molecule.

Is proposed a modification of P- α B by attaching peptide motifs with antiplatelet activity. Our work showed that modifications of P- α B by attachment of peptide motifs with antiplatelet activity leads to the appearance of antiaggregant activity in the resulting peptides that mimic the spatial structure of erythropoietin α -helix B. As the 3 peptide motifs used in this study, the possibilities of including RGD, KGD, and PGP motifs in the amino acid sequence were studied. It is known that these motifs have pronounced antiplatelet properties^{16,17,19}.

In our study, we incubated blood samples with the studied pharmacological and received a pronounced effect to different degrees. It is noteworthy that the modification of the initial peptide by attaching tripeptide motifs to its n-terminal and c-terminal led to different changes in the antiplatelet properties of the obtained compounds. The results of our study indicate that the RGD motif attached to the n-terminal terminal leads to the appearance of pronounced antiplatelet properties in the obtained P- α B1 peptide, which resulted in a statistically significant increase in platelet aggregation time by 11% ($p < 0.05$) and a decrease in its degree by 8.8% ($p < 0.05$). At the same time, the P- α B2 compound containing the RGD motif at the c-terminal portion of the peptide does not have antiplatelet properties. The KGD motif determined the statistically significant antiplatelet properties of the obtained peptides P- α B3 and P- α B4 in both the n-terminal and c-terminal regions of the peptide. But a more pronounced activity was still found in the P- α B3 compound containing the KGD motif at the n-terminal. The PGP motif included in the peptides at the n-terminal (P- α B5) and c-terminal (P- α B6) did not change the antiplatelet properties of the base peptide, and the compounds P- α B5 and P- α B6 showed procoagulant activity.

Thus, we confirmed that our proposed compounds P- α B1, P- α B3 and P- α B4 that mimic the erythropoietin α -helix B have pronounced antiagregant activity, and further studies of the obtained molecules will answer the questions of using these compounds as peptides with endothelioprotective and cytoprotective activity.

Conclusion

Based on the study, antiplatelet activity was detected in the samples: P- α B1, P- α B3, and P- α B4, which is expressed in the shift of the platelet aggregation curve to the right. The data obtained indicate an increase in platelet aggregation time and a decrease in its degree.

Acknowledgments

The study was supported by the Ministry of Science and Higher Education of the Russian Federation (subsidy agreement No. 05.605.21.0191, the unique identifier of the agreement is RFMEFI60519X0191).

References

1. Herrington, W., Lacey, B., Sherliker, P., Armitage, J., Lewington, S., 2016. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. *Circulation Research*, 12:535–546. DOI: 10.1161/CIRCRESAHA.115.307611.
2. Colin, S., Chinetti-Gbaguidi, G., Staels, B., 2014. Macrophage phenotypes in atherosclerosis. *Immunological reviews*, 262,153–166. DOI: 10.1111/imr.12218
3. Adamson, S., Leitinger, N., 2011. Phenotypic modulation of macrophages in response to plaque lipids. *Current opinion in lipidology*, 22:335–342. DOI: 10.1097/MOL.0b013e32834a97e4
4. Bolick, D.T., Skafien, M.D., Johnson, L.E., Kwon, S.C., Howatt, D., Daugherty, A., Ravichandran, K.S., Hedrick, C.C. 2009. G2A deficiency in mice promotes macrophage activation and atherosclerosis. *Circulation research*. V.104.P.318–327. DOI: 10.1161/CIRCRESAHA.108.181131
5. Wang, X.Q., Panousis, C.G., Alfaro, M.L., Evans G.F., Zuckerman S.H. 2002. Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway. *Arteriosclerosis, thrombosis, and atherosclerosis*. 22:5–9. DOI: 10.1161/01.atv.0000018287.03856.dd
6. Brand, K., Mackman, N., Curtiss, L.K. 1993, Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. *The Journal of Clinical Investigation*, 91:2031–2039. doi: 10.1172/JCI116425
7. Peled, M., Fisher, E.A., 2014. Dynamic Aspects of Macrophage Polarization during Atherosclerosis Progression and Regression. *Frontiers in immunology*, 5:579. doi: 10.3389/fimmu.2014.00579
8. Chinetti-Gbaguidi, G., Staels, B., 2011. Macrophage polarization in metabolic disorders: functions and regulation. *Current opinion in lipidology*. 22:365–372. DOI: 10.1097/MOL.0b013e32834a77b4
9. Nekoui, A., Blaise, G. 2017. Erythropoietin and Nonhematopoietic Effects. *Am J Med Sci*. 353(1):76–81. DOI: 10.1016/j.am-

jms.2016.10.009.

10. Millet, A., Bouzat, P., Trouve-Buisson, T., Batandier, C., Pernet-Gallay, K., Gaide-Chevronnay, L., 2016. Erythropoietin and its derivatives modulate mitochondrial dysfunction after diffuse traumatic brain injury. *J Neurotrauma*, 33(17):1625–1633. DOI: 10.1089/neu.2015.4160.
11. Qin, C., Zhou, S., Xiao, Y., Chen, L., 2014. Erythropoietin enhances mitochondrial biogenesis in cardiomyocytes exposed to chronic hypoxia through Akt/eNOS signalling pathway. *Cell Biol Int*, 38(3): 335–342. DOI: 10.1002/cbin.10205.
12. Peresyphkina, A.A., Pokrovskii, M.V., Gubareva, V.O., Dolzhikov A.A., 2018. Protective effect of carbamylated darbepoetin on the model of ischemic neuropathy of the optic nerve in rats. *Ekspierimental'naya I Klinicheskaya Farmakologiya*, 81(7),8–13 (In Russian). DOI:10.30906/0869-2092-2018-81-7-8-13.
13. Korokina, L.V., Kolesnik, I.M., Pokrovskii, M.V., Belous, A.S., Artyushkova, E.B., Pokrovskaya, T.G., Gudyrev, O.S., Korolev, A.E., Pavlova, L.A., Novikov, O.O., 2009. Pharmacological correction of L-NAME induced nitric oxide deficiency by recombinant erythropoietin. *Kuban Scientific Medical Bulletin*, 9(114):66–69 (In Russian).
14. Denisjuk, T.A., Pokrovskii, M.V., 2016. The combined use of recombinant erythropoietin and statins in endotoxin-induced endothelial dysfunction. *Allergology and immunology*, 7(1):63–65 (In Russian).
15. Korokin, M.V., Soldatov, V.O., Tietze, A.A., Golubev, M.V., Belykh, A.E., Kubekina, M.V., Puchenkova, O.A., Denisjuk, T.A., Gureyev, V.V., Pokrovskaya, T.G., Gudyrev, O.S., Zhuchenko, M.A., Zatolokina, M.A., Pokrovskiy, M.V., 2019. 11-amino acid peptide imitating the structure of erythropoietin α -helix b improves endothelial function, but stimulates thrombosis in rats. *Pharmacy & Pharmacology*, 7(6):312–320. (in Russian) DOI:10.19163/2307-9266-2019-7-6-312-320
16. Pytela, R., Pierschbacher, M.D., Ginsberg, M.H., Plow, E.F., & Ruoslahti, E. 1986. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. *Science*, 231(4745):1559–62. DOI: 10.1126/science.2420006.
17. Hung, Y., Kuo, Y., Huang, S., & Huang, T. 2017. Trimucrin, an Arg-Gly-Asp containing disintegrin, attenuates myocardial ischemia-reperfusion injury in murine by inhibiting platelet function. *European Journal of Pharmacology*, 813:24–32. DOI: 10.1016/j.ejphar.2017.07.039.
18. Babieva, N. S., Zhedunova, L. G., Sudakova, Y. E., Petrova, E. A., Tyurina, N. A., & Mikhailova, I. V. (2019). Specific features of the type of attitude to pregnancy and gestation dominance in women. *Electronic Journal of General Medicine*, 16(6).
19. Doğan, T., Yetim, M., Kalçık, M., Kocamış, S. İ., Dönmez, O., & Bekar, L. (2019). The Relationship between the Retinal Nerve Fiber Layer Thickness and the Presence of Fragmented QRS Complexes in Patients with Hypertension. *Journal of Clinical and Experimental Investigations*, 10(1), em00719.